KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) EBIT Margin (2016 - 2026)

Pfizer has reported EBIT Margin over the past 18 years, most recently at 286.83% for Q1 2026.

  • Quarterly EBIT Margin rose 2760.0% to 286.83% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 72.46% through Mar 2026, down 4104.0% year-over-year, with the annual reading at 33.13% for FY2025, 47426.0% up from the prior year.
  • EBIT Margin was 286.83% for Q1 2026 at Pfizer, down from 23.64% in the prior quarter.
  • Over five years, EBIT Margin peaked at 47.01% in Q3 2022 and troughed at 2483.26% in Q3 2024.
  • The 5-year median for EBIT Margin is 196.8% (2023), against an average of 341.58%.
  • Year-over-year, EBIT Margin plummeted -164612bps in 2024 and then surged 214196bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 45.55% in 2022, then plummeted by -938bps to 381.77% in 2023, then tumbled by -550bps to 2483.26% in 2024, then skyrocketed by 101bps to 23.64% in 2025, then crashed by -1313bps to 286.83% in 2026.
  • Per Business Quant, the three most recent readings for PFE's EBIT Margin are 286.83% (Q1 2026), 23.64% (Q4 2025), and 341.3% (Q3 2025).